Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia

References

• World Health Organization. Schizophrenia. 2022 [cited 2023 27 Jun]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
   Google Scholar
• Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–1306. doi: 10.1093/schbul/sbs130
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203. doi: 10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• GBD. 2016 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017; 16(2): 163–180. doi: 10.1002/wps.20420
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659–674. doi: 10.1016/j.euroneuro.2018.03.008
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi: 10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2–3):97–103. doi: 10.1016/j.schres.2009.09.019
   PubMed Web of Science ®Google Scholar
• Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. doi: 10.1177/0269881119889296
   PubMed Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. AJP. 2020;177(9):868–872. doi: 10.1176/appi.ajp.2020.177901
   Google Scholar
• Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616. doi: 10.1177/0706743717720448
   PubMed Web of Science ®Google Scholar
• NICE. Overview | psychosis and schizophrenia in adults: prevention and management | guidance | NICE. 2014 [cited 2023 Jun 27]. Available from: https://www.nice.org.uk/Guidance/CG178.
   Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. Int J Psychiatry Clin Pract. 2017;21(2):82–90. doi: 10.1080/13651501.2017.1291839
   PubMed Web of Science ®Google Scholar
• Citrome L, Eramo A, Clement F, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:3095–3104. doi: 10.2147/NDT.S91917
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82–91. doi: 10.1001/archpsyc.60.1.82
   PubMed Web of Science ®Google Scholar
• Correll CU, Agid O, Crespo-Facorro B, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022;36(7):659–679. doi: 10.1007/s40263-022-00932-2
   PubMed Web of Science ®Google Scholar
• Citrome L, JP M, Saklad SR Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10(3): 163–177. doi: 10.3371/1935-1232.10.3.163
   PubMedGoogle Scholar
• Guinart D, Taipale H, Rubio JM, et al. Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull. 2021;47(6):1621–1630. doi: 10.1093/schbul/sbab062
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599–1613.
   PubMed Web of Science ®Google Scholar
• Otsuka America Pharmaceutical, Inc. Abilify (Aripiprazole), 2004. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21436slr006_abilify_lbl.pdf.
   Google Scholar
• Allergan, Inc. Saphris (Asenapine), 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8.
   Google Scholar
• Otsuka America Pharmaceutical, Inc. Rexulti (Brexpiprazole), 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850.
   Google Scholar
• Allergan, Inc. Vraylar (Cariprazine), 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f.
   Google Scholar
• Vanda Pharmaceuticals Inc. Fanapt (iloperidone); 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b.
   Google Scholar
• Intra-Cellular Therapies, Inc. Caplyta (lumateperone); 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5.
   Google Scholar
• Sumitomo Pharma Amercia, Inc. Latuda (lurasidone); 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8.
   Google Scholar
• Eli Lilly and Company. Zyprexa (olanzapine); 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Invega (paliperidone); 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916.
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Seroquel (quetiapine fumarate). In: Sifton DW, Senior Associate Editor: Murray L, editors. Physicians’ desk reference: PDR. Montvale (NJ): Medical Economics Company, Inc, 2000. p. 562–566.
   Google Scholar
• AstraZeneca. Seroquel XR (quetiapine XR); 2022. Available from: http://www.azpicentral.com/seroquel-xr/seroquelxr.pdf.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Risperdal (Risperidone). 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0.
   Google Scholar
• Roerig. Geodon (ziprasidone); 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8326928a-2cb6-4f7f-9712-03a425a14c37.
   Google Scholar
• Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–147.
   PubMed Web of Science ®Google Scholar
• Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229–237. doi: 10.2174/157488609789006985
   PubMedGoogle Scholar
• Citrome L. Number needed to treat and number needed to harm: what are they good for? Eur Neuropsychopharmacol. 2023;68:105–107. doi: 10.1016/j.euroneuro.2022.12.006
   PubMed Web of Science ®Google Scholar
• Citrome L, Durgam S, Edwards JB, et al. Lumateperone for the treatment of schizophrenia: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Clin Psychiatry. 2023;84(2):22r14631. doi: 10.4088/JCP.22r14631
   PubMed Web of Science ®Google Scholar
• Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. Tardive dyskinesia—key differences in pathophysiology and clinical management. Neurol Ther. 2018;7(2):233–248.
   PubMed Web of Science ®Google Scholar
• Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191–208. doi: 10.2165/00002018-200528030-00002
   PubMed Web of Science ®Google Scholar
• DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33(5): 599–602. doi: 10.1001/archpsyc.1976.01770050055008
   PubMed Web of Science ®Google Scholar
• Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997;54(21):2461–2477. doi: 10.1093/ajhp/54.21.2461
   PubMed Web of Science ®Google Scholar
• Thippaiah SM, Fargason RE, Birur B Struggling to find effective pharmacologic options for akathisia? B-CALM! Psychopharmacol Bull 2021; 51: 72–78. 3
   PubMedGoogle Scholar
• Pringsheim T, Gardner D, Addington D, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018;63(11):719–729. doi: 10.1177/0706743718760288
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–356. doi: 10.1002/wps.20567
   PubMed Web of Science ®Google Scholar
• Zareifopoulos N, Katsaraki M, Stratos P, et al. Pathophysiology and management of akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. Eur Rev Med Pharmacol Sci. 2021;25(14):4746–4756. doi: 10.26355/eurrev_202101_26386
   PubMed Web of Science ®Google Scholar
• Boyd-Kimball D, Gonczy K, Lewis B, et al. Classics in Chemical Neuroscience: Chlorpromazine. ACS Chem Neurosci. 2019;10(1):79–88. doi: 10.1021/acschemneuro.8b00258
   PubMed Web of Science ®Google Scholar
• de Germay S, Montastruc F, Carvajal A, et al. Drug-induced parkinsonism: revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55–59. doi: 10.1016/j.parkreldis.2019.12.011
   PubMed Web of Science ®Google Scholar
• Siafis S, Wu H, Wang D, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. Epub ahead of print 3 Aug 2023;28(8):3267–3277. doi: 10.1038/s41380-023-02203-y
   PubMed Web of Science ®Google Scholar
• Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–457. doi: 10.1016/j.schres.2013.11.041
   PubMed Web of Science ®Google Scholar
• Kannarkat GT, Caroff SN, Morley JF. Risk of Drug-induced movement disorders with newer antipsychotic agents. Tremor Other Hyperkinet Mov (N Y). 2022;12(1):19. doi: 10.5334/tohm.695
   PubMedGoogle Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–340. doi: 10.1002/wps.20579
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi: 10.2147/PPA.S124658
   PubMed Web of Science ®Google Scholar
• Bjarke J, Gjerde HN, Jørgensen HA, et al. Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatr 2022; 34(5): 282–288. doi: 10.1017/neu.2022.9
   PubMed Web of Science ®Google Scholar
• Seemüller F, Lewitzka U, Bauer M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry. 2012;45(7):292–296. doi: 10.1055/s-0032-1309004
   PubMed Web of Science ®Google Scholar
• Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22(3):293–299. doi: 10.1097/YCO.0b013e32832a16da
   PubMed Web of Science ®Google Scholar
• Stahl SM, Lonnen AJM The mechanism of drug-induced Akathsia. CNS Spectr 2011;16(1):7–10. Stahl.
   Web of Science ®Google Scholar
• Caroff SN, Jain R, Morley JF Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry 2020; 32: 198–208. 3
   PubMed Web of Science ®Google Scholar
• Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323–332. doi: 10.1080/14737175.2018.1455504
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. doi: 10.1016/S2215-0366(19)30416-X
   PubMed Web of Science ®Google Scholar
• Burghardt KJ, Goodrich JM, Lines BN, et al. The influence of metabolic syndrome and sex on the DNA methylome in schizophrenia. Int J Genomics. 2018;2018:8076397. doi: 10.1155/2018/8076397
   PubMed Web of Science ®Google Scholar
• Bretler T, Weisberg H, Koren O, et al. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 2019;17(1):112. doi: 10.1186/s12916-019-1346-1
   PubMedGoogle Scholar
• Khasanova AK, Dobrodeeva VS, Shnayder NA, et al. Blood and urinary biomarkers of antipsychotic-induced metabolic syndrome. Metabolites. 2022;12(8):726. doi: 10.3390/metabo12080726
   PubMed Web of Science ®Google Scholar
• Ward KM, Yeoman L, McHugh C, et al. Atypical antipsychotic exposure may not differentiate metabolic phenotypes of patients with schizophrenia. Pharmacotherapy. 2018;38(6):638–650. doi: 10.1002/phar.2119
   PubMed Web of Science ®Google Scholar
• Grajales D, Ferreira V, Ám V. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 2019; 8(11): 1336. doi: 10.3390/cells8111336
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021;18(2):136–145. doi: 10.1038/s41569-020-00463-7
   PubMed Web of Science ®Google Scholar
• Goldfarb M, De Hert M, Detraux J, et al. Severe mental illness and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(9):918–933. doi: 10.1016/j.jacc.2022.06.017
   PubMed Web of Science ®Google Scholar
• Lambert AM, Parretti HM, Pearce E, et al. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: a systematic review and meta-analysis. PLoS Med. 2022;19(4):e1003960. doi: 10.1371/journal.pmed.1003960
   PubMed Web of Science ®Google Scholar
• Qadir ZS, Kar N, Ball PA, et al. Antipsychotic Use: cross-sectional opinion survey of psychiatrists in India and United Kingdom. Pharmacy. 2023;11(5):162. doi: 10.3390/pharmacy11050162
   Web of Science ®Google Scholar
• Barton BB, Segger F, Fischer K, et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295–314. doi: 10.1080/14740338.2020.1713091
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601. doi: 10.2337/diacare.27.2.596
   PubMed Web of Science ®Google Scholar
• De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99–105. doi: 10.1192/bjp.bp.110.084665
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20: 218–233. 3
   PubMedGoogle Scholar
• Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. Focus (Am Psychiatr Publ). 2021;19(1):116–128. doi: 10.1176/appi.focus.19103
   PubMedGoogle Scholar
• Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168–1178. doi: 10.1176/appi.ajp.2020.19121279
   PubMed Web of Science ®Google Scholar
• de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16(1): 341. doi: 10.1186/s12888-016-1049-5
   PubMed Web of Science ®Google Scholar
• Goh KK, Chen C-H, Lu M-L. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract 2019; 23(1): 14–32. doi: 10.1080/13651501.2018.1449864
   PubMed Web of Science ®Google Scholar
• Vasiliu O. Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: a systematic review. Exp Ther Med. 2023;26(1):355. doi: 10.3892/etm.2023.12054
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Citrome L, Cummings H, et al. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. CNS Spectr. 2023;28(3):288–299. doi: 10.1017/S1092852922000116
   PubMed Web of Science ®Google Scholar
• Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523–1631. doi: 10.1152/physrev.2000.80.4.1523
   PubMed Web of Science ®Google Scholar
• Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64–73. doi: 10.1592/phco.29.1.64
   PubMed Web of Science ®Google Scholar
• Gupta S, Lakshmanan DAM, Khastgir U, et al. Management of antipsychotic-induced hyperprolactinaemia. BJPsych Adv. 2017;23(4):278–286. doi: 10.1192/apt.bp.115.014928
   Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291–2314. doi: 10.2165/00003495-200464200-00003
   PubMed Web of Science ®Google Scholar
• Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22(2_suppl):90–97. doi: 10.1177/0269881107087373
   PubMedGoogle Scholar
• Keks N, Hope J, Schwartz D, et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020;34(5):473–507. doi: 10.1007/s40263-020-00718-4
   PubMed Web of Science ®Google Scholar
• Kane JM, Durgam S, Satlin A, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. Int Clin Psychopharmacol. 2021;36(5):244–250. doi: 10.1097/YIC.0000000000000371
   PubMed Web of Science ®Google Scholar
• Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther. 2007;32(2):197–198. doi: 10.1111/j.1365-2710.2007.00806.x
   PubMed Web of Science ®Google Scholar
• Antoniou C-K, Dilaveris P, Manolakou P, et al. QT prolongation and malignant arrhythmia: how serious a problem? Eur Cardiol. 2017;12(2):112–120. doi: 10.15420/ecr.2017:16:1
   PubMedGoogle Scholar
• Patel PJ, Borovskiy Y, Killian A, et al. Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: findings from the penn atrial fibrillation free study. Heart Rhythm. 2016;13(2):527–535. doi: 10.1016/j.hrthm.2015.11.008
   PubMed Web of Science ®Google Scholar
• Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc. 2016;5(6):e003264. doi: 10.1161/JAHA.116.003264
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D, et al. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760–781. doi: 10.1124/pr.110.003723
   PubMed Web of Science ®Google Scholar
• MGH Center for Women’s Menta Health. National pregnancy registry for psychiatric medications ©. MGH Center For Women’s Mental Health [cited 2023 Jun 29]. Available from: https://womensmentalhealth.org/research/pregnancyregistry/.
   Google Scholar
• Kulkarni J, Storch A, Baraniuk A, et al. Antipsychotic use in pregnancy. Expert Opin Pharmacother. 2015;16(9):1335–1345. doi: 10.1517/14656566.2015.1041501
   PubMed Web of Science ®Google Scholar
• Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–192. doi: 10.1097/01.pra.0000351878.45260.94
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. doi: 10.1001/jamapsychiatry.2016.1520
   PubMed Web of Science ®Google Scholar
• McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–449. quiz 546. doi: 10.4088/JCP.v66n0406
   PubMed Web of Science ®Google Scholar
• Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–462. doi: 10.1097/JCP.0b013e318295fe12
   PubMed Web of Science ®Google Scholar
• Leek JC, Arif H. Pregnancy medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. cited 2023 Sep 23. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507858/
   Google Scholar
• Kennedy MLH. Medication management of bipolar disorder during the reproductive years. Ment Health Clin. 2017;7(6):255–261. doi: 10.9740/mhc.2017.11.255
   PubMedGoogle Scholar
• Heinonen E, Forsberg L, Nörby U, et al. Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. CNS Drugs. 2022;36(5):529–539. doi: 10.1007/s40263-022-00908-2
   PubMed Web of Science ®Google Scholar
• Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13(11):e1002160. doi: 10.1371/journal.pmed.1002160
   PubMed Web of Science ®Google Scholar
• Pennazio F, Brasso C, Villari V, et al. Current status of therapeutic drug monitoring in mental health treatment: a review. Pharmaceutics. 2022;14(12):2674. doi: 10.3390/pharmaceutics14122674
   PubMed Web of Science ®Google Scholar
• Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. J Clin Psychopharmacol. 2016;36(3):244–252. doi: 10.1097/JCP.0000000000000491
   PubMed Web of Science ®Google Scholar
• MGH Center for Women’s Menta Health. Center for Women’s Mental Health at MGH. MGH Center For Women’s Mental Health [cited 2023 Jun 29]. Available from: https://womensmentalhealth.org/.
   Google Scholar
• National Library of Medicine, NIH. Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development, 2006.
   Google Scholar
• Springer Publishing. Hale’s Medications & Mothers’ Milk [cited 2023 Jun 29]. Available from: https://www.halesmeds.com/.
   Google Scholar
• AstraZeneca Pharmaceuticals. Seroquel (quetiapine).
   Google Scholar
• Beunk L, Nijenhuis M, Soree B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet. [31 Mar 2023]. Epub ahead of print. doi: 10.1038/s41431-023-01347-3
   Web of Science ®Google Scholar
• Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62. doi: 10.1053/j.ackd.2010.05.010
   PubMedGoogle Scholar
• Center for Drug Evaluation and Researc (CDER). Pharmacokinetics in patients with impaired renal function — study design, Data Analysis, and impact on dosing and labeling; 2020 [cited 2023 Sep 14]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing-and.
   Google Scholar
• Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med 2021; 385(19): 1737–1749. doi: 10.1056/NEJMoa2102953
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021;26(2):118–129. doi: 10.1017/S1092852921000249
   Web of Science ®Google Scholar
• Citrome L, Walling DP, Zeni CM, et al. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study. J Clin Psychiatry. 2020;82(1):20m13602. doi: 10.4088/JCP.20m13602
   PubMed Web of Science ®Google Scholar
• Chang JG, Roh D, Kim C-H. Association between Therapeutic Alliance and adherence in outpatient schizophrenia patients. Clin Psychopharmacol Neurosci. 2019;17(2):273–278. doi: 10.9758/cpn.2019.17.2.273
   PubMed Web of Science ®Google Scholar
• Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717–724. doi: 10.1001/archpsyc.62.7.717
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20. doi: 10.1186/1471-244X-12-20
   PubMed Web of Science ®Google Scholar
• Adelufosi AO, Adebowale TO, Abayomi O, et al. Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry. 2012;34(1):72–79. doi: 10.1016/j.genhosppsych.2011.09.001
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10(1):2. doi: 10.1186/1471-244X-10-2
   PubMed Web of Science ®Google Scholar